A Precision Strike: A Biotech Duo Takes Aim at a Leading Cause of Blindness

PORTLAND, Ore. and ENSCHEDE, The Netherlands – July 08, 2026

In a move that signals a potential shift in the battle against a leading cause of irreversible vision loss, biotechnology firm Cascade Prodrug Inc. and medical technology company Uneedle have announced an advanced collaboration. The partnership aims to pair a novel, highly targeted therapeutic with a precision microneedle delivery system to treat neovascular, or “wet,” age-related macular degeneration (AMD). This strategic alliance seeks to address the significant shortcomings of current treatments by developing a therapy that is not only more effective but also less burdensome for the millions of patients affected globally.

The collaboration will combine Cascade's first-in-class, hypoxia-targeted drug, CPD100, with Uneedle's Bella-Vue suprachoroidal microneedle system. The companies are set to present their initial progress at the upcoming OIS 9th Retina Innovation Summit, offering a first public glimpse into a technology that could redefine the standard of care.

The Heavy Burden of a Breakthrough Therapy

For nearly two decades, the treatment landscape for wet AMD—a disease responsible for an estimated 90% of all AMD-related blindness—has been dominated by anti-vascular endothelial growth factor (anti-VEGF) therapies. These drugs, such as Eylea and Vabysmo, have been nothing short of revolutionary, saving the sight of countless individuals by halting the abnormal growth of leaky blood vessels in the back of the eye.

Yet, this success comes at a steep price: a relentless treatment burden. The standard of care involves frequent injections directly into the vitreous of the eye, a procedure that is both uncomfortable and disruptive. Patients often require injections every one to three months, a schedule that proves difficult to maintain in the real world. Studies consistently show that this grueling regimen leads to undertreatment, which in turn results in suboptimal vision outcomes over the long term. For an aging patient population, the logistical challenges of frequent clinic visits, coupled with procedural anxiety, create significant barriers to care.

Beyond the burden of administration, current therapies are not a panacea. A substantial portion of patients, up to 45% by some estimates, show a limited response to anti-VEGF drugs. Furthermore, long-term use has raised concerns about potential side effects, including the development of macular atrophy, a condition that can cause its own form of irreversible vision loss. This complex reality has created a clear and urgent unmet need for more durable, safer, and less frequent treatment options.

A Two-Pronged Attack on Pathological Angiogenesis

The partnership between Cascade Prodrug and Uneedle represents a direct and sophisticated response to these challenges. Instead of simply creating a longer-lasting version of an existing drug, their approach combines a novel therapeutic mechanism with a state-of-the-art delivery platform for a synergistic effect.

The first component is Cascade's CPD100. It is a “hypoxia-targeted” therapeutic, meaning it is designed to activate specifically in the low-oxygen environments characteristic of the pathological blood vessels that define wet AMD. In vitro studies have shown that CPD100 selectively induces cell-cycle arrest and apoptosis (programmed cell death) in the endothelial cells forming these unwanted vessels, while crucially preserving the viability of healthy retinal cells. This “smart bomb” approach differs fundamentally from the broader action of anti-VEGFs, promising a targeted strike on the disease source while minimizing collateral damage to the delicate retinal tissue essential for vision.

“By combining CPD100’s hypoxia-targeted mechanism of action with Uneedle’s Bella-Vue suprachoroidal microneedle system, we believe we can create a compelling therapeutic approach designed to address pathological angiogenesis while preserving retinal integrity,” said Allan Cochrane, President of Cascade Prodrug Inc.

Complementing this targeted drug is Uneedle's Bella-Vue delivery system. The platform uses a hollow microneedle to precisely deliver therapeutics into the suprachoroidal space (SCS)—a potential pathway located between the sclera and the choroid. Delivering a drug to this space allows for higher concentrations to reach the target tissues of the choroid and retina, where wet AMD originates, while potentially reducing exposure to other parts of the eye. This could not only enhance the drug's efficacy and durability but also improve its safety profile by minimizing risks associated with traditional intravitreal injections.

“CPD100 represents a highly differentiated therapeutic approach for wet AMD, and we are pleased that Cascade has selected Bella-Vue to support targeted delivery to the suprachoroidal space,” stated Jeroen Wissink, CEO of Uneedle. “This collaboration reflects our commitment to enabling partners with a precise, validated microneedle platform for the next generation of ophthalmic therapeutics.”

Navigating the Path from Lab to Clinic

While the scientific premise is compelling, the journey from a promising concept to an approved therapy is long and fraught with challenges. The collaboration's immediate strategy demonstrates a clear understanding of this path. Initial in vivo studies have already confirmed the tolerability of administering a therapy via the Bella-Vue system, and a preclinical proof-of-concept study for CPD100 is now underway.

A crucial next step is a planned INTERACT meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026. This early engagement is a savvy move, particularly for a novel drug-device combination product. It allows the companies to get early feedback on their preclinical data and clinical trial designs, helping to de-risk the complex regulatory process and streamline the path toward an Investigational New Drug (IND) application.

Parallel to these regulatory steps, Cascade is actively securing the necessary funding to complete its chemistry, manufacturing, and controls (CMC) activities and the nonclinical GLP-enabling studies required for IND clearance. This dual focus on scientific validation and operational readiness is critical for any small biotech aiming to compete in the high-stakes pharmaceutical landscape.

Charting a Course in a Crowded Field

The Cascade and Uneedle partnership does not enter the market in a vacuum. The wet AMD space is fiercely competitive, with established blockbusters from Regeneron and Roche/Genentech and a robust pipeline of next-generation therapies. Competitors are pursuing various strategies to reduce treatment burden, including gene therapies from companies like AbbVie/Regenxbio that promise a “one-and-done” treatment, and sustained-release implants from EyePoint Pharmaceuticals and Ocular Therapeutix.

However, the collaboration's key differentiator lies in its unique, dual-pronged innovation. It is not merely a longer-acting anti-VEGF or a new delivery method for an old drug. It is a fundamentally new therapeutic mechanism delivered via a novel, targeted route. If preclinical proof-of-concept studies can demonstrate that this synergy leads to superior efficacy, a better safety profile, or a significantly longer duration of action, the partnership could carve out a significant position in the market.

For the millions of patients navigating the challenges of living with wet AMD, this collaboration represents more than just a business venture; it offers a glimmer of hope for a future where preserving sight does not require such a demanding and frequent sacrifice. The success of CPD100 and the Bella-Vue system in upcoming trials will be watched closely by patients, clinicians, and investors alike, as it could mark the next major leap forward in the fight against this debilitating disease.